Estimates of the prevalence and number of Fibromyalgia syndrome patients and their alpha-1 antitrypsin phenotypic distribution in ten countries
(2007) In Journal of Musculoskeletal Pain 15(4). p.41540-41540- Abstract
- Objectives: During the last few years, clinical, epidemiological, and pathological evidence has suggested that inherited alpha-1 antitrypsin [AAT] deficiency might play a role in the development of the fibromyalgia syndrome [FMS], probably because of the loss of AAT anti-inflammatory efficacy. The objective of this study was to estimate the prevalence and number of FMS patients, and their AAT phenotypic distribution worldwide. Methods: A critical review selecting reliable studies on the subject. Results: Studies on AAT gene frequencies and FMS prevalence were retrieved for ten countries worldwide, namely Canada, the United States of America [USA], Denmark, Finland, Germany, Italy, the Netherlands, Spain, Sweden, and Pakistan. The severe... (More)
- Objectives: During the last few years, clinical, epidemiological, and pathological evidence has suggested that inherited alpha-1 antitrypsin [AAT] deficiency might play a role in the development of the fibromyalgia syndrome [FMS], probably because of the loss of AAT anti-inflammatory efficacy. The objective of this study was to estimate the prevalence and number of FMS patients, and their AAT phenotypic distribution worldwide. Methods: A critical review selecting reliable studies on the subject. Results: Studies on AAT gene frequencies and FMS prevalence were retrieved for ten countries worldwide, namely Canada, the United States of America [USA], Denmark, Finland, Germany, Italy, the Netherlands, Spain, Sweden, and Pakistan. The severe deficiency Z allele was found in all these countries, with very high frequencies in Denmark and Sweden [23 and 27 per 1,000, respectively], high frequencies in Italy and Spain [16 and 17], intermediate frequencies in Germany, the Netherlands, Canada, and the USA [10 to 14], and a low frequency in Pakistan [nine per 1,000]. The calculated prevalence of AAT deficiency and the number of FMS patients with AAT deficiency were 1/10 and 25,408 in Canada, 1/11 and 478,681 in the US, 1/9 and 3,124 in Denmark, 1/36 and 726 in Finland, 1/16 and 48,523 in Germany, 1/13 and 84,876 in Italy, 1115 and 9,639 in the Netherlands, 1/4 and 114,359 in Spain, 1/11 and 9,065 in Sweden, and 1/25 and 85.965 in Pakistan. Our calculations predict that AAT deficiency would remain undetected in around nine percent of FMS patients, with about eight percent of them carrying moderate deficiency phenotypes [MS, SS, and MZ], and less than one percent with severe deficiency phenotypes [SZ and ZZ]. Conclusions: Therefore, AAT phenotype characterization should be recommended in FMS patients and the possible efficacy of AAT replacement therapy in severe deficiency FMS patients should warrant further Studies. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/688915
- author
- Blanco, Ignacio ; de Serres, Frederick ; Janciauskiene, Sabina LU ; Arbesu, Daniel ; Fernandez-Bustillo, Enrique ; Carcaba, Victoriano ; Nita, Izabela and Astudillo, Aurora
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- alpha-1, fibromyalgia syndrome, fibromyalgia syndrome prevalence, antitrypsin deficiency, epidemiological studies
- in
- Journal of Musculoskeletal Pain
- volume
- 15
- issue
- 4
- pages
- 41540 - 41540
- publisher
- Haworth Press
- external identifiers
-
- wos:000249136100003
- scopus:34548682068
- ISSN
- 1540-7012
- DOI
- 10.1300/J094v15n04_03
- language
- English
- LU publication?
- yes
- id
- 21fa4afd-ac8a-4036-bdc9-f1cb2e2e91bf (old id 688915)
- date added to LUP
- 2016-04-01 11:45:59
- date last changed
- 2022-01-26 17:56:41
@article{21fa4afd-ac8a-4036-bdc9-f1cb2e2e91bf,
abstract = {{Objectives: During the last few years, clinical, epidemiological, and pathological evidence has suggested that inherited alpha-1 antitrypsin [AAT] deficiency might play a role in the development of the fibromyalgia syndrome [FMS], probably because of the loss of AAT anti-inflammatory efficacy. The objective of this study was to estimate the prevalence and number of FMS patients, and their AAT phenotypic distribution worldwide. Methods: A critical review selecting reliable studies on the subject. Results: Studies on AAT gene frequencies and FMS prevalence were retrieved for ten countries worldwide, namely Canada, the United States of America [USA], Denmark, Finland, Germany, Italy, the Netherlands, Spain, Sweden, and Pakistan. The severe deficiency Z allele was found in all these countries, with very high frequencies in Denmark and Sweden [23 and 27 per 1,000, respectively], high frequencies in Italy and Spain [16 and 17], intermediate frequencies in Germany, the Netherlands, Canada, and the USA [10 to 14], and a low frequency in Pakistan [nine per 1,000]. The calculated prevalence of AAT deficiency and the number of FMS patients with AAT deficiency were 1/10 and 25,408 in Canada, 1/11 and 478,681 in the US, 1/9 and 3,124 in Denmark, 1/36 and 726 in Finland, 1/16 and 48,523 in Germany, 1/13 and 84,876 in Italy, 1115 and 9,639 in the Netherlands, 1/4 and 114,359 in Spain, 1/11 and 9,065 in Sweden, and 1/25 and 85.965 in Pakistan. Our calculations predict that AAT deficiency would remain undetected in around nine percent of FMS patients, with about eight percent of them carrying moderate deficiency phenotypes [MS, SS, and MZ], and less than one percent with severe deficiency phenotypes [SZ and ZZ]. Conclusions: Therefore, AAT phenotype characterization should be recommended in FMS patients and the possible efficacy of AAT replacement therapy in severe deficiency FMS patients should warrant further Studies.}},
author = {{Blanco, Ignacio and de Serres, Frederick and Janciauskiene, Sabina and Arbesu, Daniel and Fernandez-Bustillo, Enrique and Carcaba, Victoriano and Nita, Izabela and Astudillo, Aurora}},
issn = {{1540-7012}},
keywords = {{alpha-1; fibromyalgia syndrome; fibromyalgia syndrome prevalence; antitrypsin deficiency; epidemiological studies}},
language = {{eng}},
number = {{4}},
pages = {{41540--41540}},
publisher = {{Haworth Press}},
series = {{Journal of Musculoskeletal Pain}},
title = {{Estimates of the prevalence and number of Fibromyalgia syndrome patients and their alpha-1 antitrypsin phenotypic distribution in ten countries}},
url = {{http://dx.doi.org/10.1300/J094v15n04_03}},
doi = {{10.1300/J094v15n04_03}},
volume = {{15}},
year = {{2007}},
}